Validation of novel ECG Parameters to detect Fabry disease and other cardiomyopathies

Validation of novel ECG Parameters to detect Fabry disease and other cardiomyopathies - DETECT

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00031596

Enrollment

600

Registered

2023-05-08

Start date

2023-04-01

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fabry disease amyloidosis Hypertrophic cardiomyopathy aortic stenosis

Interventions

Group 1: Patients with Fabry disease Group 2: Patients with cardiomyopathies (such as amyloidosis, aortic stenosis, hypertrophic cardiomyopathy) and controls

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Existing cardiomyopathy: Fabry disease, amyloidosis, hypertrophic cardiomyopathy, aortic valve stenosis, and healthy controls with ECGs

Exclusion criteria

Exclusion criteria: Insufficient quality of the ECGs

Design outcomes

Primary

Measure	Time frame
ECG parameters for differentiating cardiomyopathies are anaylzed using an algorithm based on artificial intelligence. ECG analysis is performed during the study period.	—

Secondary

Measure	Time frame
Sensitivity/specificity values as well as accuracy values of ECG parameters	—

Countries

Germany

Contacts

Public ContactIsabel Mattig

Deutsches Herzzentrum der Charité

isabel.mattig@dhzc-charite.de+4930450613305

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Jun 11, 2026